La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Imugene Gestione

Gestione criteri di controllo 1/4

Imugene's Il CEO è Leslie Chong, nominato in Nov2016, e ha un mandato di 7.75 anni. la retribuzione annua totale è A$ 2.48M, composta da 30.2% di stipendio e 69.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.17% delle azioni della società, per un valore di A$ 4.46M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 5.9 anni.

Informazioni chiave

Leslie Chong

Amministratore delegato

AU$2.5m

Compenso totale

Percentuale dello stipendio del CEO	30.2%
Mandato del CEO	7.8yrs
Proprietà del CEO	1.2%
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Leslie Chong rispetto agli utili di Imugene?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-AU$150m
Mar 31 2024	n/a	n/a	-AU$119m
Dec 31 2023	n/a	n/a	-AU$89m
Sep 30 2023	n/a	n/a	-AU$64m
Jun 30 2023	AU$2m	AU$750k	-AU$38m
Mar 31 2023	n/a	n/a	-AU$39m
Dec 31 2022	n/a	n/a	-AU$40m
Sep 30 2022	n/a	n/a	-AU$39m
Jun 30 2022	AU$1m	AU$600k	-AU$38m
Mar 31 2022	n/a	n/a	-AU$33m
Dec 31 2021	n/a	n/a	-AU$27m
Sep 30 2021	n/a	n/a	-AU$23m
Jun 30 2021	AU$789k	AU$408k	-AU$18m
Mar 31 2021	n/a	n/a	-AU$15m
Dec 31 2020	n/a	n/a	-AU$12m
Sep 30 2020	n/a	n/a	-AU$11m
Jun 30 2020	AU$733k	AU$375k	-AU$11m
Mar 31 2020	n/a	n/a	-AU$10m
Dec 31 2019	n/a	n/a	-AU$9m
Sep 30 2019	n/a	n/a	-AU$8m
Jun 30 2019	AU$777k	AU$350k	-AU$8m
Mar 31 2019	n/a	n/a	-AU$7m
Dec 31 2018	n/a	n/a	-AU$6m
Sep 30 2018	n/a	n/a	-AU$5m
Jun 30 2018	AU$403k	AU$300k	-AU$4m

Compensazione vs Mercato: La retribuzione totale di Leslie ($USD 1.66M ) è superiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 650.58K ).

Compensazione vs guadagni: La retribuzione di Leslie è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Leslie Chong

7.8yrs

Mandato

AU$2,482,687

Compensazione

Ms. Leslie Chong served as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020 until July 2023. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Hopper	Executive Chairman	11.9yrs	AU$515.23k	5.57% A$ 25.4m
Leslie Chong	CEO, MD & Executive Director	7.8yrs	AU$2.48m	1.17% A$ 5.3m
Michael Tonroe	CFO & Company Secretary	2yrs	AU$839.00k	Nessun dato
Nicholas Ede	Head of Corporate Development	less than a year	AU$874.91k	0.24% A$ 1.1m
Monil Shah	Chief Business Officer	3.3yrs	AU$799.20k	Nessun dato
Bradley Glover	Chief Operating Officer	1.1yrs	Nessun dato	Nessun dato
Ursula McCurry	Chief Clinical Operations Officer	2.7yrs	Nessun dato	Nessun dato
John Byon	Senior Vice President of Clinical Development	less than a year	Nessun dato	Nessun dato
Joseph Woodard	Chief Medical Officer	less than a year	Nessun dato	Nessun dato

1.5yrs

Durata media

57yo

Età media

Gestione esperta: Il team dirigenziale di IMU non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Paul Hopper	Executive Chairman	11.9yrs	AU$515.23k	5.57% A$ 25.4m
Leslie Chong	CEO, MD & Executive Director	6.5yrs	AU$2.48m	1.17% A$ 5.3m
Jens Eckstein	Independent Non-Executive Director	5.3yrs	AU$115.52k	0.29% A$ 1.3m
Kimberlee Drapkin	Non-Executive Director	1.3yrs	AU$2.08k	0.0050% A$ 22.9k
Yuman Fong	Chair of Oncolytic Virotherapy Scientific Advisory Board	4.8yrs	Nessun dato	Nessun dato
Ursula Wiedermann	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Neil Segal	Member of Scientific Advisory Board	10.4yrs	Nessun dato	Nessun dato
Josep Tabernero Caturla	Member of Scientific Advisory Board	5.9yrs	Nessun dato	Nessun dato
Yelena Janjigian	Scientific Advisory Board Member	8.4yrs	Nessun dato	Nessun dato
Peter Schmid	Member of Scientific Advisory Board	6.8yrs	Nessun dato	Nessun dato
Tanios Bekaii-Saab	Member of Scientific Advisory Board	6yrs	Nessun dato	Nessun dato
Pravin T. Kaumaya	Member of Scientific Advisory Board	5.9yrs	Nessun dato	Nessun dato

6.0yrs

Durata media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IMU sono considerati esperti (durata media dell'incarico 5.9 anni).

Imugene Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited, Annual General Meeting, Nov 30, 2023

Less than half of directors are independent

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Recent updates

New minor risk - Financial position

Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

Forecast to breakeven in 2027

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

Price target decreased by 8.2% to AU$0.34

New minor risk - Share price stability

Imugene Limited, Annual General Meeting, Nov 30, 2023

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 14% to AU$0.42

Less than half of directors are independent

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Price target decreased by 14% to AU$0.42

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Imugene Appoints Dr Weitzman Interim Chief Medical Officer

Forecast to breakeven in 2026

Imugene Limited Announces Board Changes

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Price target decreased by 9.8% to AU$0.46

Imugene Limited Announces VAXINIA Trial Advances to Combination Cohort 1 & Monotherapy Cohort 3

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Receives Vaxinia Ethics Approval in Australia

Imugene Limited Presents New and First CHECKvacc Data At the 2022 San Antonio Breast Cancer Symposium

Imugene Limited Announces First Patient Dosed in VAXINIA Intravenous Cohort 2

Insufficient new directors

Price target decreased to AU$0.52

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Independent Non-Executive Director exercised options to buy AU$3.2m worth of stock.

Imugene Limited Announces That First Patient Dosed in VAXINIA Intratumoral Cohort 2

Imugene Limited, Annual General Meeting, Nov 17, 2022

Price target decreased to AU$0.51

Imugene Limited Announces First patient IV dosed in VAXINIA Phase 1 clinical trial

Imugene Limited Announces That Australian Government's Office of the Gene Technology Regulator (Ogtr) Has Granted Imugene the Dir Licence Required to Expand Its Vaxinia Phase 1 Clinical Trial Within Australia

Consensus forecasts updated

Price target decreased to AU$0.52

Imugene Limited Doses First Patient in nextHERIZON Phase 2 Trial

Imugene Appoints Jakob Dupont as Non- Executive Director

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Announces First Cohort 3 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Appoints Mike Tonroe as Chief Financial Officer, Effective from September 2022

Imugene Limited Announces Appointment of Dr. Sharon Yavrom as Executive Director, Clinical Scientist

Imugene Limited Announces Final HER-Vaxx Phase 2 Trial Overall Survival Results

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$1.5m worth of stock.

Imugene Limited Announces Board Changes

City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors

Imugene Limited Receives Ethics Approval to Start Phase 2 nextHERIZON Clinical Trial of Cancer Immunotherapy HER-VAXX

Imugene Limited Announces First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

Consensus forecasts updated

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Imugene Limited Announces Appointment of Steven Cha as Chief Medical Officer and Member of the Executive Management Team

Imugene Limited Receives Notice of Grant from the European Patent Office for Patent Application Number

Imugene Completes Phase 1a Monotherapy Dose Escalation of Immunotherapy PD1-Vaxx

Executive Chairman recently sold AU$37m worth of stock

Imugene Limited Receives US Food and Drug Administration (FDA) Investigational New Drug (IND) Approval to Initiate A Phase I Clinical Trial of its Oncolytic Virotherapy Candidate, Vaxinia (CF33-hNIS, HOV2)

Imugene Limited Provides Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc

Insider recently sold AU$1.4m worth of stock

Imugene Limited Provides Phase 1 Clinical Trial Update of Its Immunotherapy Pd1-Vaxx

Imugene Presents HER-Vaxx Update at ESMO World GI Congress

Imugene Limited Announces FDA IND Approval of New Oncolytic Virotherapy Checkvacc Virotherapy Checkvacc

CEO, MD & Executive Director exercised options and sold AU$1.6m worth of stock

Independent Non-Executive Director recently sold AU$1.2m worth of stock